Ravi Thadhani

Ravi Thadhani

Auto-generated profile, based on publicly available information

Ravi Thadhani

Office of the Chief Academic Officer, Partners HealthCare, Boston, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2006 in Atherosclerosis
Verified
Journal Article
Closed access
JPJennifer K. Pai
Jennifer K. Pai
SHSusan E. Hankinson
Susan E. Hankinson
RTRavi Thadhani
Ravi Thadhani
NRNader Rifai
Nader Rifai
TPTobias Pischon
Tobias Pischon
EREric Rimms
Eric Rimms


15 February 2024 in The FASEB Journal
Verified
Journal Article
Closed access
RTRavi Thadhani
Ravi Thadhani
ACAna Sofia Cerdeira
Ana Sofia Cerdeira
SKS. Ananth Karumanchi
S. Ananth Karumanchi

1 November 2001 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
MWMyles Wolf
Myles Wolf
EKElizabeth Cnm Kettyle
Elizabeth Cnm Kettyle
LSLaura Sandler
Laura Sandler
JEJeffrey L. Ecker
Jeffrey L. Ecker
JRJames Michael Roberts
James Michael Roberts
RTRavi Thadhani
Ravi Thadhani
OBJECTIVE Systemic inflammation might contribute to the pathogenesis of preeclampsia. In addition, the association between obesity and inflammation in preeclampsia has not been examined in detail. We determined whether first-trimester elevation of serum C-reactive protein, an index of systemic inflammation, was associated with preeclampsia. METHODS We conducted a prospective, nested case-control study among women enrolled in the Massachusetts General Hospital Obstetrical Maternal Study cohort. High-resolution C-reactive protein assays were performed on first-trimester (11 ± 2 weeks' gestation) serum samples in 40 women in whom preeclampsia developed (blood pressure [BP] greater than 140/90 mmHg, and proteinuria, either 2+ or more by dipstick or greater than 300 mg per 24 hours), and in 80 matched controls. This sample size had greater than 80% power to detect a difference in C-reactive protein levels between cases and controls. We used non-parametric tests to compare C-reactive protein levels and conditional logistic regression to control for confounding variables. RESULTS First-trimester C-reactive protein levels were significantly higher among women in whom preeclampsia subsequently developed compared with controls (4.6 compared with 2.3 mg/L, P = .04). When women were subdivided into C-reactive protein quartiles, the odds ratio (OR) of being in the highest quartile of C-reactive protein was 3.2 (95% confidence interval [CI] 1.1, 9.3, P = .02) among cases of preeclampsia compared with controls. When body mass index (BMI) was added to the multivariable model, the highest quartile of C-reactive protein was no longer associated with increased risk of preeclampsia (OR 1.1, 95% CI .3, 4.3, P = .94). In the same model without BMI, the highest quartile of C-reactive protein was associated with increased risk of preeclampsia (OR 3.5, 95% CI 1.3, 9.5, P = .01). CONCLUSION In women with preeclampsia, there was evidence of increased systemic inflammation in the first trimester. Inflammation might be part of a causal pathway through which obesity predisposes to preeclampsia.

12 December 2019 in European Heart Journal - Cardiovascular Pharmacotherapy
Verified
Journal Article
Open access
PDF file
DBDebasish Banerjee
Debasish Banerjee
NCNihil Chitalia
Nihil Chitalia
ISIrina Chis Ster
Irina Chis Ster
EAEvan Appelbaum
Evan Appelbaum
RTRavi Thadhani
Ravi Thadhani
DGDavid Goldsmith
David Goldsmith
Vitamin D deficiency is associated with cardiovascular events in chronic kidney disease (CKD) yet the impact of supplementation is controversial. Previous active vitamin D supplementation studies did not show improvement in cardiac structure or function but the effect of native vitamin D supplementation in CKD patients with low vitamin D levels is unknown. We have addressed this question via both a randomized double-blind prospective study and a meta-analysis of three randomized placebo-controlled studies. We conducted a randomized double-blind, placebo-controlled trial of vitamin D supplementation in stable, non-diabetic, CKD three to four patients with circulating vitamin D <75nmol/L, who were receiving treatment with ACEi or ARB and had high-normal left ventricular (LV) mass. Patients were randomized to receive six directly observed doses of 100 000 IU cholecalciferol (n = 25) or matched placebo (n = 23). The primary endpoint was changed in LV mass index (LVMI) over 52 weeks, as assessed by cardiac magnetic resonance imaging. Secondary endpoints included changes in LV ejection fraction (LVEF); LV and right ventricular volumes and left and right atrial area. Vitamin D concentration increased with the administration of cholecalciferol. The change in LVMI with cholecalciferol [median (inter-quartile range), −0.25 g (−7.20 to 5.30)] was no different from placebo [−4.30 g (9.70 to 2.60)]. There was no difference in changes of LVEF; LV and right ventricular volumes and left and right atrial area. The meta-analysis of three 52-week, randomized placebo-controlled studies using active/native vitamin D supplementation showed no differences in LVMI measurements. Vitamin D supplementation does not have beneficial effects on LV mass in CKD patients.

27 April 2026 in Nature Medicine
Verified
Journal Article
Closed access
RTRavi Thadhani
Ravi Thadhani
THThomas F. Hiemstra
Thomas F. Hiemstra
MVManu Vatish
Manu Vatish
HSHolger Stepan
Holger Stepan
ACAna Sofia Cerdeira
Ana Sofia Cerdeira
SKS. Ananth Karumanchi
S. Ananth Karumanchi